Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Gregory Frost

Halozyme Therapeutics, Inc.

Switzerland Innovation Park Basel Area provides ready-made and customizable workspaces for various teams, focusing on innovation in healthcare, life sciences, and technology.

Switzerland Innovation Park Basel Area

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Syneos Health, Inc.

Idorsia is engaged in the discovery, development, and commercialization of innovative medicines to help patients.

Metric
Company Name	Idorsia Ltd	Halozyme Therapeutics, Inc.	Switzerland Innovation Park Basel Area	Syneos Health, Inc.
Symbol	IDIA	HALO		SYNH
MSH ID	COM:IDORSIA	COM:HALOZYME	COM:SIP-BASELAREA	COM:SYNEOSHEALTH
Market	STOCKS	STOCKS	PRIVATE	STOCKS
Sector		Healthcare	Commercial & Professional Services	Healthcare
Industry		Biotechnology	Real Estate	Medical - Diagnostics & Research
Country	CH	US	CH	US
Stage	Post-IPO Debt
Employee Count	636	373		28.77K
Website	idorsia.com	halozyme.com	sip-baselarea.com	syneoshealth.com
LinkedIn		halozyme-therapeutics-inc-	switzerland-innovation-park-basel-area
Founders

Metric
Market Cap	311.77M	6.74B	4.46B
Enterprise Value
Monthly Web Traffic	19.83K	7.62K
Web Traffic Growth	1.09	-0.80
Valuation
Raised Capital	83.54M

Metric
Revenue	173.71M	829.25M	5.39B
Revenue (LTM)
Revenue (NTM)
Gross Profit	143.86M	636.89M	1.25B
EBITDA	-597.34M	422.43M	699.99M
Operating Income	-619.04M	337.57M	403.19M
Net Income	-339.61M	281.59M	266.50M
EPS	-1.90	2.13	2.57
Diluted EPS	-1.90	2.10	2.54
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.95	0.79	0.22
Operating Profit Margin	-0.52	0.46	0.05
EBITDA Margin	-3.44	0.51	0.13
Net Profit Margin	0.31	0.39	0.01
Return on Equity	0.44	2.05	0.02
Return on Assets	0.06	0.17	0.01
Return on Capital Employed	-0.29	0.22	0.05

COM:IDORSIA

Idorsia

Last Close

0.77

25/11 09:15

Market Cap

273.49M

Beta: -

Volume Today

109.95K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.73	17.53	62.57
P/B Ratio	-0.33	17.86	1.28
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.46	9.34	0.82
EV Multiple	14.37	14.08	3.00

Metric
Days Sales Outstanding	52.13	101.60	114.47
Days Payables Outstanding	751.10	38.70	11.85
Days Inventory Outstanding	2.47K	331.59	0.01
Operating Cycle	2.52K	414.45	114.48
Cash Conversion Cycle	1.77K	388.24	102.63
Asset Turnover	0.28	0.48	0.67

Metric
Operating Cash Flow	-717.35M	388.57M
Free Cash Flow	-728.06M	373.28M
Cash Flow to Debt	-0.35	0.29	0.09
Operating Cash Flow/Sales	-3.00	0.50	0.05
Free Cash Flow Yield	-2.60	0.08	0.04

Metric
Cash & Equivalents	165.35M	118.37M	112.00M
Accounts Receivable	-14.68M	-3.34M
Inventory	67.42M	127.60M
Goodwill		416.82M	4.90B
Debt to Capitalization	11.32	0.95	0.45
Debt to Assets	1.85	0.79	0.36
Current Ratio	1.21	7.63	1.20
Quick Ratio	1.00	6.21	1.09

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.18	0.04	0.01
R&D to Revenue	1.94	0.10
SG&A to Revenue	4.00